Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

NCT05230901 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Aortic Stenosis, Severe

Interventions

OTHER: Standard of Care
DRUG: Spironolactone 25mg
DRUG: Dihydralazine

Sponsor

University Medical Center Goettingen